Thiopurine Methyl Transferase at Chughtai Lab

Thiopurine Methyl Transferase at Chughtai Lab

Thiopurine Methyltransferase (TPMT) is an essential intracellular enzyme that plays a pivotal role in the metabolic pathway of thiopurine immunosuppressive medications. These drugs, which include azathioprine, 6-mercaptopurine (6-MP), and 6-thioguanine (6-TG), are widely prescribed for the management of complex medical conditions. These conditions include inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis, autoimmune disorders like rheumatoid arthritis and systemic lupus erythematosus, and hematological malignancies, most notably acute lymphoblastic leukemia (ALL). The primary function of the TPMT enzyme is the S-methylation of thiopurines, converting them into inactive metabolites, thereby regulating the amount of active drug available in the body.

When a patient has low or absent TPMT enzyme activity, the thiopurine drugs are preferentially metabolized through an alternative pathway into active thioguanine nucleotides (6-TGNs). While 6-TGNs are necessary for the therapeutic immunosuppressive effect, an excessive accumulation of these active metabolites due to a TPMT deficiency leads to severe, life-threatening bone marrow suppression (myelosuppression). This clinical complication manifests as profound leukopenia, thrombocytopenia, and anemia, leaving the patient highly vulnerable to severe infections and bleeding. Conversely, patients with exceptionally high TPMT activity may experience therapeutic failure because they rapidly clear the drug, or they may develop hepatotoxicity due to the overproduction of methylated metabolites like 6-methylmercaptopurine (6-MMP). Therefore, determining a patient’s TPMT status before initiating thiopurine therapy is a crucial step in personalized medicine, allowing clinicians to tailor drug dosages or select alternative therapeutic agents.

Chughtai Lab, Pakistan’s premier diagnostic network, offers the Thiopurine Methyl Transferase test by outsourcing the specimen to leading specialized reference laboratories in the United Kingdom. This international outsourcing arrangement ensures that patients and clinicians in Pakistan have access to world-class molecular and enzymatic testing with the highest standards of accuracy, clinical reliability, and quality assurance. By utilizing this advanced diagnostic service at Chughtai Lab, healthcare providers can confidently implement personalized treatment plans, maximize therapeutic efficacy, and significantly minimize the risk of severe drug-induced toxicities.

Clinical Procedure: What to Expect

Patient Preparation

Appropriate patient preparation is essential to ensure the clinical accuracy of the Thiopurine Methyl Transferase test, particularly when evaluating phenotypic enzyme activity. Patients should observe the following guidelines:

• No Fasting Required: There is generally no requirement for dietary fasting before this test. Patients can eat and drink normally prior to sample collection.
• Blood Transfusion History: This is the most critical preparation factor. If the patient has received a red blood cell (RBC) transfusion within the past 30 to 90 days, they must inform the healthcare provider and the laboratory staff. Transfused red blood cells contain normal donor TPMT enzymes, which can temporarily mask a patient’s true deficient status in a phenotypic enzyme activity test, leading to a falsely normal result. In such cases, genetic (genotypic) testing may be preferred, or the test may need to be postponed.
• Medication Review: Patients must provide a complete list of all current medications, especially any thiopurine drugs (azathioprine, 6-mercaptopurine) or other drugs that may inhibit TPMT activity, such as sulfasalazine, mesalamine, or allopurinol.
• Hydration: Staying well-hydrated is recommended as it helps facilitate easier venous access during sample collection.

During the Procedure

The collection of the sample for the Thiopurine Methyl Transferase test is a standard, minimally invasive procedure carried out by highly trained phlebotomists at Chughtai Lab:

• Patient Positioning: The patient is comfortably seated, and the phlebotomist identifies a suitable vein, typically in the antecubital fossa (inner elbow).
• Sanitization: The skin over the selected vein is thoroughly cleansed with an antiseptic swab to prevent any contamination.
• Sample Collection: A sterile needle is inserted into the vein, and a whole blood sample is drawn into an EDTA (purple-top) tube. For molecular or enzymatic testing, maintaining the integrity of the whole blood sample is paramount.
• Post-Collection Care: Once the sample is collected, the needle is gently removed, and a sterile cotton ball or adhesive bandage is applied to the puncture site. The patient is advised to apply gentle pressure for a few minutes to prevent bruising.
• Cold Chain Logistics: Because this test is outsourced to a specialized reference laboratory in the United Kingdom, Chughtai Lab enforces strict cold chain logistics. The sample is immediately processed, stabilized, and packaged under temperature-controlled conditions to preserve enzyme activity and DNA integrity during international transit.
• Safety and Comfort: The entire venipuncture process takes less than five minutes and is associated with minimal discomfort, similar to a brief prick.

When is a Thiopurine Methyl Transferase Test Performed?

Inflammatory Bowel Disease (IBD) Management

Gastroenterologists routinely request the TPMT test before initiating immunomodulator therapy with azathioprine or 6-mercaptopurine for patients diagnosed with Crohn’s disease or ulcerative colitis. Because these chronic inflammatory conditions require long-term maintenance therapy to sustain remission, establishing the patient’s metabolic capacity beforehand prevents the sudden onset of severe bone marrow suppression, ensuring a safer therapeutic course.

Acute Lymphoblastic Leukemia (ALL) Treatment

In pediatric and adult oncology, 6-mercaptopurine is a cornerstone of maintenance chemotherapy protocols for Acute Lymphoblastic Leukemia. Because oncology patients are already undergoing intensive, myelosuppressive treatments, any additional, unexpected drug toxicity can be fatal. Oncologists utilize the TPMT test to identify patients who require drastic dose reductions (often up to 90% lower than standard doses) or alternative non-thiopurine therapies.

Rheumatoid Arthritis and Autoimmune Disorders

Rheumatologists frequently prescribe azathioprine as a steroid-sparing agent for patients with severe rheumatoid arthritis, systemic lupus erythematosus (SLE), or autoimmune hepatitis. To avoid severe adverse drug reactions and to determine a safe, individualized starting dose, a baseline TPMT assessment is performed before the first dose of the medication is administered.

Monitoring for Unexplained Myelosuppression

If a patient who is already undergoing treatment with thiopurine medications experiences a sudden, unexplained drop in their complete blood count (CBC) parameters—such as severe leukopenia, neutropenia, or thrombocytopenia—physicians will order this test. This helps determine whether the hematological toxicity is due to an underlying genetic TPMT deficiency or other clinical factors.

Pre-Therapeutic Screening

In modern clinical practice, pre-therapeutic screening is recognized as a standard of care for any patient for whom thiopurine therapy is being considered. This proactive screening approach helps avoid trial-and-error dosing, reduces the incidence of emergency hospitalizations due to drug toxicity, and provides clinicians with the genetic or enzymatic data necessary to optimize patient care from day one.

What Does a Thiopurine Methyl Transferase Test Detect?

The Thiopurine Methyl Transferase test is designed to detect and quantify the functional activity of the TPMT enzyme or identify specific genetic mutations in the TPMT gene. The primary clinical findings and parameters detected by this test include:

• Normal/High TPMT Activity: Indicates that the patient possesses two normal, functional copies of the TPMT gene (homozygous wild-type), allowing them to metabolize thiopurine drugs at a standard rate.
• Intermediate TPMT Activity: Indicates that the patient has one normal allele and one non-functional variant allele (heterozygous), resulting in moderately reduced enzyme activity and an increased risk of toxicity.
• Low or Deficient TPMT Activity: Indicates that the patient has two non-functional variant alleles (homozygous mutant), resulting in little to no enzyme activity and an extremely high risk of life-threatening myelosuppression.
• TPMT*2 Allele: Detection of the specific G238C single nucleotide polymorphism (SNP) associated with reduced enzyme stability.
• TPMT*3A Allele: Detection of the most common variant allele in Caucasian populations, containing both the G460A and A719G mutations, which leads to rapid degradation of the enzyme.
• TPMT*3C Allele: Detection of the variant allele containing the A719G mutation, which is highly prevalent in Asian and African populations.
• TPMT*3B Allele: Identification of the rare variant containing only the G460A mutation.
• TPMT*4 Allele: Detection of a rare non-functional allele associated with a splicing defect.
• Enzyme Activity Levels: Quantitative measurement of TPMT activity in red blood cells, typically reported in units per gram of hemoglobin (U/g Hb).
• Risk of Profound Myelosuppression: Identification of patients at critical risk of bone marrow failure.
• Risk of Severe Neutropenia: Assessment of the likelihood of developing critically low neutrophil counts.
• Risk of Severe Thrombocytopenia: Assessment of the likelihood of developing critically low platelet counts.
• Risk of Severe Anemia: Evaluation of the risk of drug-induced red blood cell depletion.
• Thiopurine-Induced Hepatotoxicity Risk: Identification of high metabolizers who may produce excessive 6-MMP, leading to liver injury.
• Therapeutic Resistance: Detection of ultra-high enzyme activity that may cause standard drug doses to be ineffective.
• Interfering Factors: Identification of potential test interference, such as recent red blood cell transfusions that alter phenotypic results.
• Need for Alternative Immunosuppressants: Clear clinical indication that alternative therapies (e.g., methotrexate or biologics) should be used instead of thiopurines.
• Need for Dose Reduction: Precise guidance indicating that a 30% to 50% dose reduction is required for intermediate metabolizers.
• Need for Extreme Dose Reduction: Precise guidance indicating that a 90% dose reduction is required for deficient metabolizers if thiopurines are absolutely necessary.
• Elevated 6-MMP Levels: Correlation with high TPMT activity, which can guide clinicians in managing liver health.
• Suboptimal 6-TGN Levels: Explanation for therapeutic failure in patients with high TPMT activity.
• Optimal 6-TGN Levels: Confirmation of appropriate metabolic balance in patients with normal TPMT activity.
• Genetic Predisposition to Adverse Drug Reactions: Comprehensive profile of the patient’s hereditary sensitivity to thiopurines.
• Pharmacogenomic Profile: Detailed genetic data that remains constant throughout the patient’s life, serving as a permanent medical record for future drug selections.

Turnaround Time and Report Access at Chughtai Lab

Because the Thiopurine Methyl Transferase test is a highly specialized investigation that is outsourced to a leading reference laboratory in the United Kingdom, the turnaround time is typically between 10 to 14 working days. This timeframe is necessary to accommodate international cold-chain shipping, customs clearance, advanced molecular or enzymatic analysis in the UK, and rigorous clinical validation by specialized pathologists. Chughtai Lab is committed to ensuring a seamless, secure, and rapid transport process to maintain specimen viability.

Once the validated test report is received from the UK reference laboratory, it is immediately uploaded to Chughtai Lab’s secure digital database. Patients and their referring physicians are notified via an automated SMS alert. The complete, highly detailed report can be accessed, viewed, and downloaded in PDF format through the official Chughtai Lab website portal or the user-friendly Chughtai Lab mobile application. This digital access ensures that patients can share their results with their healthcare providers without delay, facilitating timely clinical decisions.

Thiopurine Methyl Transferase Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
TPMT Genotype	Homozygous wild-type (normal alleles, e.g., *1/*1)	Heterozygous or homozygous variant alleles (e.g., *2, *3A, *3C)
TPMT Enzyme Activity	Normal enzymatic activity (typically >25.0 U/g Hb, reference ranges may vary)	Low activity (intermediate: 15.0 – 25.0 U/g Hb) or deficient activity (<15.0 U/g Hb)
Myelosuppression Risk	Low/Standard risk under standard drug dosages	High risk (intermediate metabolizers) or extremely high/fatal risk (deficient metabolizers)
Thiopurine Dosage Guidance	Standard starting dose of azathioprine or 6-mercaptopurine	30% to 50% dose reduction (intermediate) or 90% reduction/alternative drug (deficient)
Hepatotoxicity Risk	Standard risk	Increased risk in ultra-high metabolizers due to elevated 6-MMP levels
Transfusion Interference	No recent blood transfusions (accurate phenotype)	Recent transfusion within 90 days (falsely normalizes phenotypic results)
Therapeutic Efficacy	Expected therapeutic response at standard doses	Therapeutic resistance (high metabolizers) or severe toxicity (deficient metabolizers)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Thiopurine Methyl Transferase?

• Experienced Healthcare Professionals: Chughtai Lab is managed by a team of highly qualified clinical pathologists, molecular biologists, and laboratory technologists dedicated to diagnostic excellence.
• Patient-Focused Care: Every step of the diagnostic process, from sample collection to reporting, is designed with patient comfort, safety, and convenience in mind.
• Quality Diagnostic Services: Chughtai Lab adheres to stringent international quality control protocols, ensuring highly accurate and reproducible test results.
• Professional Reporting: Reports are comprehensive, clear, and structured to provide actionable clinical insights for referring physicians.
• Modern Diagnostic Approach: By partnering with leading international reference laboratories in the UK, Chughtai Lab brings advanced global diagnostics to patients in Pakistan.
• Comfortable Environment: All Chughtai Lab collection centers are designed to provide a clean, professional, and welcoming environment for patients.
• Convenient Location: With a vast network of collection centers across Lahore, Karachi, Islamabad, and other major cities, accessing quality diagnostics is easy.
• Commitment to Accurate Diagnosis: Chughtai Lab’s robust logistics and cold-chain management guarantee that outsourced samples reach international destinations in optimal condition.